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Human 
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of Encephalitis in 
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Laura A. Benjamin, Penny Lewthwaite, 
Ravi Vasanthapuram, Guoyan Zhao, Colin Sharp, 
Peter Simmonds, David Wang, and Tom Solomon
To investigate whether uncharacterized infectious 
agents were associated with neurologic disease, we 
analyzed cerebrospinal fl uid specimens from 12 children 
with acute central nervous system infection. A high-
throughput pyrosequencing screen detected human 
parvovirus 4 DNA in cerebrospinal fl uid of 2 children with 
encephalitis of unknown etiology. 
Encephalitis is a major cause of death and disability globally. In Asia, Japanese encephalitis virus is the 
most commonly recognized cause, with 30,000–50,000 
cases and ≈10,000 deaths annually (1). However, for 
most encephalitis cases, the cause is unknown, even with 
comprehensive screening for recognized agents (1).
The advent of high-throughput sequencing technologies 
enabled the direct characterization of microbial nucleic 
acid from clinical samples and revolutionized the process 
for identifying potential etiologic agents of disease. A 
key feature is that the method is unbiased and can detect 
any nonhost nucleic acid sequences present in a sample. 
It has the potential to detect expected agents, known but 
unexpected agents, and novel agents (2).
Human parvovirus 4 (PARV4) is a single-stranded 
DNA virus fi rst detected in 2005 (3). Infections with PARV4 
are accompanied by acute viremia for several weeks (C. 
Sharp et al., unpub. data), followed by seroconversion for 
antibody and virus clearance. As observed with another 
human parvovirus, parvovirus B19, there is long term 
persistence of viral DNA sequences in several tissues but 
not the brain (4). We describe 2 children in southern India 
with suspected encephalitis and high PARV4 levels in their 
cerebrospinal fl uid (CSF).
The Study
We obtained CSF from a cohort of children (<16 years 
of age) hospitalized with a suspected acute central nervous 
system (CNS) infection at the Vijayanagar Institute of 
Medical Sciences, Bellary, India, October 2005–October 
2007, as previously described (5). Suspected CNS infection 
was defi ned as a febrile illness (for <2 weeks) and >1 of 
the following signs or symptoms: severe headache, altered 
mental status, seizures, or focal neurologic signs (6).
To investigate whether uncharacterized infectious 
agents were associated with neurologic disease, we 
obtained CSF specimens from 12 patients with acute 
CNS infection (i.e., febrile illness with CSF leukocyte 
count >5 cells/mm3 or protein >45 mg/dL). These patients 
had negative diagnostic test results for pathogens known 
to cause CNS infection in this region of India at the 
time of investigation (e.g., Japanese encephalitis virus, 
chikungunya virus, dengue fever virus, and Plasmodium 
falciparum); in addition, CSF culture was performed and 
no bacterial organisms were found (5). Total nucleic acid 
was extracted from whole CSF and randomly amplifi ed 
as previously described with the modifi cation that 6-nt 
barcodes were added to the 5′ end of the primers used 
for the amplifi cation (7). The amplifi ed materials were 
pooled together and processed by using a high-throughput 
pyrosequencing technique on a GS FLX Titanium Platform 
(454 Life Sciences/Roche, Branford, CT, USA).
The raw sequence reads were deconvoluted on the basis 
of the barcode and then processed through a standardized 
bioinformatic pipeline (2). The sequences of interest were 
then categorized into taxonomy groups based on the best 
BLAST (www.ncbi.nlm.nih.gov/BLAST/) hit. For 2 of the 
12 patients, patients VES085 and VES065, viral sequences 
were detected in the CSF.
We identifi ed 17 (92.6%–98.2% sequence identity) 
distinct sequence reads in the CSF of patient VES085 
and 6 (95.6%–98.9% sequence identity) distinct reads 
from patient VES065 with pairwise identities based on 
BLASTn alignment of each read to the reference genome 
(GenBank accession no. EU175855.1). To verify the 
results, we used PARV4-specifi c PCR primers to screen 
all 12 original CSF samples as described (8). Only 
samples from VES085 and VES065 were positive; all 
other samples were negative by PCR.
PARV4 viral loads in the 2 CSF samples and the 
corresponding serum sample from 1 patient collected 
contemporaneously were semiquantifi ed by limiting 
dilution PCR by using primers on 5 replicate samples of 
each dilution. The PCR conditions demonstrated single 
copy sensitivity (data not shown), and endpoint titers 
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of 50% positivity were calculated by using the Reed-
Muench formula (8,9). Both the CSF and 1 serum sample 
demonstrated high endpoint titers, indicating acute 
infection and substantial virus spread into the CNS of the 2 
patients (Table 1).
To genetically characterize PARV4 variants infecting 
the patients, we generated overlapping sets of amplicons 
spanning the complete genome of PARV4 from the 3 
samples. No variation was seen between the CSF and 
serum-derived sequences from VES085. The fully 
assembled coding regions of the variants generated from 
both patients were compared to previously described 
PARV4 variants (n = 18 viral proteins 2/1 and n = 19 
nonstructural sequences) (Table 2). Phylogenetic analysis 
demonstrated that both variants belonged to genotype 2 
(Figure). All sequences have been submitted to GenBank 
(accession nos. HQ593530–HQ593532).
The serum sample was screened for immunoglobulin 
(Ig) G and IgM PARV4-specifi c antibodies by using a 
previously developed serologic assay for PARV4 antibodies 
(10). The serum of VES085 was IgM positive and IgG 
negative, consistent with an acute infection (Table 1).
Through serologic screening of age-matched 
controls, we were able to largely rule out the possibility 
that detection of PARV4 DNA in samples from 2 of the 
12 patients was simply incidental to a high background 
incidence of PARV4 infection in this age group. Although 
published data on the duration of viremia in patients with 
acute PARV4 infections has not been directly determined, 
viral loads as found in the study patients are of relatively 
short duration in other parvovirus infections (16 days for 
viral loads >5,000 DNA copies/mL in the case of B19) 
(11). Furthermore, through testing sequential samples 
from persons exposed to PARV4, we have found no 
persons with viremia duration of >6 weeks (C. Sharp et 
al., unpub. data). Using the 6-week (maximum) estimate 
and a background incidence of infection of 2.2% per year 
(based on the detection of 4/41 seropositive children 
with a mean age of 4.5 years), the likelihood of viremia 
detection would be at most 0.25%, a fi gure consistent with 
the actual measured absence of viremia detection in the 
control cohort.
Conclusions
PARV4 is a recently identifi ed virus found in human 
blood and in a variety of tissues but with no known disease 
association. In this study we detected PARV4 DNA in 2 of 
12 CSF samples from patients with suspected encephalitis 
of unknown cause in southern India. Unfortunately, no 
samples were available from the wider cohort for further 
testing. The presence of PARV4 DNA and IgM against 
PARV4 in acute-phase serum from the 1 child with this 
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Table 1. Clinical and laboratory characteristics of children with CSF positive for human parvovirus 4, India*
ID, date of 
illness 
Age,
y Clinical course Outcome 
CSF Serum 
PCR WCC†
Protein,
mg/dL 
Glucose,
mg/dL IgM IgG PCR
VES085,
 2006 Jan 
2 Prodomal illness for 12 
days; febrile with frequent 
generalized convulsions 
during first week of 
admission; CSF 
examination on day 12 of 
illness 
Discharged
against medical 
advice on day 
18 after 
admission 
+
1.5 x 107
copies/mL
4 59 32 + ? +
5.6 x 109
copies/mL
VES065
2005 Nov 
3 Prodomal illness for 9 
days; febrile, poor 
appetite, and a 
generalized convulsion on 
day 9; CSF examination 
on day 9 of illness 
Recovered on 
day 14 with no 
residual
neurologic
deficit 
+
3.2 x 105
copies/mL
8 15 60 NA NA NA
*CSF, cerebrospinal fluid; ID, patient identification code; WCC, leukocyte count; Ig, immunoglobulin; +, positive; ?, negative; NA, not available. 
†Leukocyte count differential 100% lymphocytes for each patient. 
Table 2. Percent divergence of the nonstructural coding region of human PARV4–positive encephalitis patients VES065 and VES085,
compared with previously described PARV4 variants* 
Patient or genotype 
Genotype 3,  
aa (nt), n = 1 
Genotype 2, 
aa (nt), n = 7 
Genotype 1, 
aa (nt), n = 11 
VES085 serum, 
aa (nt), n = 1
VES085 CSF, 
aa (nt), n = 1 
VES065 CSF, 
aa (nt), n = 1 
VES065 CSF,  n = 1 9.5 (3.5) 3.7 (1.5) 10.3 (3.7) 0.2 (0.0) 0.2 (0.0) 
VES085 CSF, n = 1 9.4 (3.5) 3.6 (1.5) 10.2 (3.7) 0.0 (0.0)  
VES085 serum, n = 1 9.4 (3.5) 3.6 (1.5) 10.2 (3.7) 
Genotype 1, n = 11 8.0 (2.6) 9.3 (2.9) 0.9 (0.6) 
Genotype 2, n = 7 8.6 (2.7) 1.8 (0.7) 
Genotype 3,  n = 1 
*PARV4, human parvovirus 4; CSF, cerebrospinal fluid. 
sample available further supports the contention that this 
was an acute infection.
Brain biopsy, the defi nitive investigation, was not 
available at the time. More often than not, clinicians have 
to rely on surrogate markers to diagnose encephalitis (e.g., 
CSF pleocytosis, febrile illness, and focal neurologic signs 
in the right clinical context). It is more common to have 
CSF pleocytosis than not, though of course there are well 
characterized cases of CNS infection (e.g., dengue) with no 
pleocytosis (6).
CSF erythrocyte count was not routinely measured in 
this resource-limited setting. Although it is theoretically 
possible the parvovirus detected in the CSF could have 
refl ected spillover from a blood-contaminated spinal tap, 
there was no overt evidence of hemorrhagic CSF. The fact 
that patient VES085 was febrile with a neurologic syndrome 
and positive serum IgM, and patient VES065 had similar 
clinical signs with high PARV4 viral CSF levels suggests 
that they did indeed have a CNS infection.
PARV4 is primarily found in injection drug users 
and persons who have received blood products; PARV4 
is therefore presumed to be transmitted parenterally. 
However, the risk for such transmission in the children 
in our study was low, which supports the possibility of an 
alternative route of transmission (8,12). HIV testing was 
not available.
The use of high-throughput sequencing for identifying 
an unexpected possible cause of CNS infection (PARV4) 
is cutting edge; this technique’s utility also extends to a 
recent identifi cation of astrovirus in a case of encephalitis 
(13). With the high seroprevalence of PARV4 infection 
highlighted in recent reports (5%–37%), there is a clear 
need to further assess the role of PARV4 in CNS infection 
across the globe (14,15). 
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